PMID- 23523564
OWN - NLM
STAT- MEDLINE
DCOM- 20140418
LR  - 20130923
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 22
IP  - 9
DP  - 2013 Sep
TI  - p38 MAPK inhibitor, CBS3830 limits vascular remodelling in arterialised vein 
      grafts.
PG  - 751-8
LID - S1443-9506(13)00069-3 [pii]
LID - 10.1016/j.hlc.2013.02.006 [doi]
AB  - OBJECTIVE: Following bypass surgery vein grafts undergo a remodelling process 
      that can lead to restenosis and ultimately vein graft failure. Signalling through 
      mitogen activated protein kinases (MAPKs) is a key mechanism involved in vein 
      graft failure. Here, we investigated whether CBS3830 (c-a-i-r biosciences GmbH, 
      Tubingen, Germany), a new highly selectively inhibitor of p38 MAPK, has a 
      significant effect on inhibiting intimal, medial and adventitial hyperplasia. 
      METHODS: Sixty specific pathogen free Sprague Dawley male rats were randomly 
      divided into three groups. The control group with a reversed right jugular vein, 
      which is common to carotid artery interposition graft, was compared with 
      sham-operated, and CBS3830 treated animals. Intimal, medial and adventitia 
      morphometric examinations and expression of proliferating cell nuclear antigen 
      (PCNA) were analysed after one, two and four weeks for vein grafts. RESULTS: 
      Intimal, medial and adventitia thickening in CBS3830 group were significantly 
      lower than in the control group at each time point. Moreover, CBS3830 
      significantly reduced the phosphorylation of p38 MAPK and PCNA expression 
      compared to the control. CONCLUSION: On the basis of the present work, intima, 
      media and adventitia of saphenous vein grafts undergo vascular remodelling after 
      surgery. The new, highly selective p38 MAPK inhibitor, CBS3830, ameliorates 
      intimal, medial, and adventitial remodelling by varying degrees.
CI  - Crown Copyright (c) 2013. Published by Elsevier B.V. All rights reserved.
FAU - Ge, Jian-Jun
AU  - Ge JJ
AD  - Department of Cardiovascular Surgery, The Cardiovascular Research Institute 
      Laboratory, 1st Hospital of AnHui Medical University, Hefei 230022, China. 
      Electronic address: aygejianjun@yahoo.cn.
FAU - Zhao, Zhi-Wei
AU  - Zhao ZW
FAU - Zhou, Zheng-Chun
AU  - Zhou ZC
FAU - Wu, Song
AU  - Wu S
FAU - Zhang, Rui
AU  - Zhang R
FAU - Pan, Fa-ming
AU  - Pan FM
FAU - Abendroth, Dietmar-Karl
AU  - Abendroth DK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130322
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Adventitia/enzymology/pathology/physiopathology
MH  - Animals
MH  - *Coronary Artery Bypass
MH  - Gene Expression Regulation/drug effects
MH  - Graft Occlusion, Vascular/enzymology/pathology/physiopathology/*prevention & 
      control
MH  - Male
MH  - Phosphorylation/drug effects
MH  - Proliferating Cell Nuclear Antigen/biosynthesis
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Saphenous Vein/*enzymology/pathology/physiopathology
MH  - Tunica Intima/*enzymology/pathology/physiopathology
MH  - p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - AVGs
OT  - Adventitia hyperplasia
OT  - Arterio-venous bypass
OT  - CHD
OT  - Con
OT  - EC
OT  - ERK
OT  - IH
OT  - Intimal hypeplasia
OT  - MAPKs
OT  - Medial hyperplasia
OT  - NIH
OT  - PCNA
OT  - PDGF-BB
OT  - PRRs
OT  - SMC
OT  - Sham
OT  - Vein graft
OT  - arterialized vein grafts
OT  - control
OT  - coronary heart disease
OT  - endothelial cells
OT  - extracellular-signal regulated kinas
OT  - intimal hyperplasia
OT  - mitogen activated protein kinases
OT  - neointimal hyperplasia
OT  - p38 MAPK
OT  - p38 MAPK-inhibitor
OT  - p38 mitogen activated protein kinases
OT  - pattern recognition receptors
OT  - platelet derived growth factor BB
OT  - proliferating cell nuclear antigen
OT  - sham-operated
OT  - smooth muscle cells
EDAT- 2013/03/26 06:00
MHDA- 2014/04/20 06:00
CRDT- 2013/03/26 06:00
PHST- 2012/06/12 00:00 [received]
PHST- 2013/02/21 00:00 [revised]
PHST- 2013/02/24 00:00 [accepted]
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2014/04/20 06:00 [medline]
AID - S1443-9506(13)00069-3 [pii]
AID - 10.1016/j.hlc.2013.02.006 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2013 Sep;22(9):751-8. doi: 10.1016/j.hlc.2013.02.006. Epub 2013 
      Mar 22.